Skip to main content
Article thumbnail
Location of Repository

Interferon Beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology

By Massimo Filippi, Marco Rovaris, R. Capra, C. Gasperini, F. Prandini, V. Martinelli, Mark A. Horsfield, S. Bastianello, Maria Pia Sormani, C. Pozzilli and G. Comi

Abstract

This is the version as published in Journal of neurology Neurosurgery and Psychiatry. http://jnnp.bmj.com/Objective—The ability of recombinant\ud human interferon â-1a (rh-IFN â-1a) to\ud suppress multiple sclerosis activity, evaluated from MRI, was assessed across a\ud range of lesions enhancing at different\ud gadolinium-DTPA (Gd) doses and with\ud different sizes.\ud Methods—Every 4 weeks, standard dose\ud (Sd; 0.1 mmol/kg Gd) and triple dose (Td;\ud 0.3 mmol/kgGd) MRI were obtained from\ud 18 patients with relapsing-remitting multiple\ud sclerosis for 3 months before and 4 months after starting treatment with 44 μg\ud rh-IFN â-1a subcutaneously, once a week.\ud Results—The total numbers of enhancing\ud lesions were 145 and 126 on Sd scans and\ud 278 and 192 on the Td scans obtained\ud before and after treatment. The introduction\ud of treatment decreased, on average, the rate of appearance of new enhancing lesions seen on Sd and Td scans by 37% (p<0.001). Treatment effects on new enhancing lesions seen on Td scans was, on average, 28% higher than on those seen on Sd scans. The distribution of lesion sizes on Td scans changed significantly during the treatment period (p=0.05), due to a marked decrease in the number of small lesions.\ud Conclusions— The effect of 44 μg rh-IFN\ud â-1a in reducing multiple sclerosis disease\ud activity, as monitored by Gd enhanced MRI, is not homogeneous, but graduated according to the pathological characteristics and size of the lesions

Publisher: BMJ Publishing Group
Year: 1999
OAI identifier: oai:lra.le.ac.uk:2381/451

Suggested articles

Citations

  1. (1996). A high-resolution three-dimensional gradient echo sequence improves the detection of disease activity in multiple sclerosis. doi
  2. (1998). A multi-center longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: implications for phase II clinical trials. doi
  3. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with multiple sclerosis.Neurology 1996;46:379–84. doi
  4. Interobserver variation in reporting gadolinium-enhanced MS lesions: consensus rules and eVect of training.
  5. (1997). Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with T2-weighted images. doi
  6. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. doi
  7. Magnetization transfer ratios in MS lesions enhancing after diVerent doses of gadolinium.Neurology 1998;50:1289–93. doi
  8. (1998). MRI evolution of new MS lesions enhancing after diVerent doses of gadolinium. doi
  9. (1983). New diagnostic criteria for multiple sclerosis: guidelines for research protocols. doi
  10. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). doi
  11. Reingold SC, the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey.Neurology 1996;46:907–11. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.